Medical Information

Ritlecitinib is a daily oral JAK inhibitor, and its standardized use requires close attention to three major aspects: standard dosage, efficacy evaluation, and full process safety monitoring. The following are the core points of clinical medication.

1、 Standard usage and dosage

Initial dose: Recommended once a day, 50mg each time, taken whole at a fixed time of the day (such as after breakfast), unaffected by food intake.

Dosage adjustment: If missed, make-up medication can be taken at least 8 hours before the next dose, otherwise skip; Do not double the dosage per day. When using potent CYP3A4 inhibitors (such as ketoconazole) in combination, follow the doctor's advice to reduce the dosage to 30mg/day.

Course management: Continuous medication, no pre-set discontinuation period, and the decision to maintain or discontinue treatment is made by the doctor after efficacy evaluation.

2、 Efficacy monitoring indicators

Target observation window: The key evaluation points are the 4th, 12th, and 24th week of treatment, and symptom scores (such as skin lesion area and severity index) need to be recorded during follow-up visits.

Efficacy evaluation: If satisfactory control is not achieved after 24 weeks (such as improvement<50% compared to baseline), the doctor will reassess whether to switch or combine other treatments.

Patient self-assessment: It is recommended to take photos of the affected area every week and record the itching/pain visual simulation score (0-10 points) for reference during follow-up visits.

3、 Core precautions during medication

Infection and laboratory tests: Blood routine and liver function will be checked every 2-4 weeks for the first 3 months before treatment; If there are signs of infection such as fever, sore throat, and frequent urination, take medication temporarily and seek medical attention.

Taboo behavior: live vaccine ban (within 4 weeks of discontinuation); Avoid combining with strong immunosuppressants (such as cyclosporine); Not recommended during lactation.

Special population: Elderly people (≥ 65 years old) do not need to adjust the dosage, but need to strengthen renal function monitoring; Mild to moderate liver injury (Child Pugh A/B) can be used, but severe use is contraindicated.

4、 Notice on Stopping and Changing Medications

Do not suddenly stop taking medication on your own (which may cause the condition to rebound), and gradually reduce the dosage under the guidance of a doctor; If the interruption exceeds 7 days due to side effects, restart from the starting dose and do not directly restore the original dose.